<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784314</url>
  </required_header>
  <id_info>
    <org_study_id>2009.587</org_study_id>
    <nct_id>NCT02784314</nct_id>
  </id_info>
  <brief_title>Cost Efficacy Evaluation of Robot Assisted Radical Prostatectomy</brief_title>
  <acronym>ROBOTCAP</acronym>
  <official_title>Medico-economic Evaluation of Robotic-assisted Radical Prostatectomy Versus Laparoscopic Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this observational cost efficacy study, the investigator compare the Laparoscopic Radical
      Prostatectomy (LRP) versus Robotic-Assisted Laparoscopic Prostatectomy (RALP). Every cost of
      care that include hospitalization related or post operative medical consumption are obtained
      and recorded up to 5 years follow up. Functional results (continence, potency, quality of
      life) are obtained through standardised questionnaires. Carcinologic results are estimated by
      Prostate Specific Antigen (PSA) relapse and salvage treatments. Economic evaluation will be
      made to estimate direct costs of the four postoperative year along with the incremental
      cost-effectiveness ratio (ICER) per successful surgical treatment (preserved urinary
      continence and erectile function and PSA &lt; 0.2).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erectile function</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Proportion of patients with recovery of erectile function between T0 (before surgery) and 12 months after surgery. Recovery is defined as a maximum decrease of 5 points score of the International Index of Erectile Function (IIEF) between pre and postoperative evaluations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical margins</measure>
    <time_frame>During surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen (PSA)</measure>
    <time_frame>Before surgery (T0), 6 months (M6), 12 months (M12), 24 months (M24) and 60 months (M60) after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continence</measure>
    <time_frame>Before surgery (T0), 6 months (M6), 9 months (M9),12 months (M12), 24 months (M24) and 60 months (M60) after surgery</time_frame>
    <description>Continence is assessed by the International Prostate Symptom Score (IPSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>Perioperative period, 6 months (M6), 12 months (M12) and 24 months (M24) afer surgery</time_frame>
    <description>Adverse events related to the perioperative prostatectomy, 6 months, 12 months and 24 months afer surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Before surgery (T0), 6 months (M6), 9 months (M9),12 months (M12) and 24 months (M24) after surgery</time_frame>
    <description>Quality of life is assessed by EQ-5D, QLQ-C30 and QLQ-PR25 scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental cost-effectiveness ratio</measure>
    <time_frame>60 months afet surgery</time_frame>
    <description>Economic evaluation will be made to estimate direct costs of the five postoperative years along with the incremental cost-effectiveness ratio (ICER) per successful surgical treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Robotic-Assisted Radical Prostatectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Robotic-Assisted Radical Prostatectomy using da Vinci Surgical System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic Radical Prostatectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard laparoscopic Radical Prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic-Assisted Radical Prostatectomy</intervention_name>
    <arm_group_label>Robotic-Assisted Radical Prostatectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic Radical Prostatectomy</intervention_name>
    <arm_group_label>Laparoscopic Radical Prostatectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Localized prostate cancer

          -  Gleason grade ≤ 3 + 4

          -  PSA &lt; 15 ng / mL

          -  Stage ≤ T2b

          -  Eligible to receive laparoscopic radical prostatectomy

          -  Candidate bilateral or unilateral erectile preservation

        Exclusion Criteria:

          -  Patient at high risk of postoperative progression (PSA&gt; 15 ng / mL; grade 5
             predominant, clinical or radiological stage T3

          -  Presenting erectile dysfunction (IIEF &lt; 22)

          -  Past history of urinary incontinence (&gt; grade 1 WHO)

          -  Body mass index &gt; 30
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service d'Urologie - Clinique St Augustin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33074</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie et Chirurgie de la Transplantation - Hôpital Edouard Herriot -Hospices Civils de Lyon</name>
      <address>
        <city>Lyon cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie - Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinically localized prostate cancer</keyword>
  <keyword>Robotic-assisted prostatectomy</keyword>
  <keyword>Laparoscopic prostatectomy</keyword>
  <keyword>Erectile function ;</keyword>
  <keyword>Cost efficacy study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

